Pharma News

Infection with the influenza virus leads to lung injury through inflammation over-activation that causes collateral damage to cells required for breathing. Such damage can be life-threatening, but scientists have a new preventative treatment. A team from St. Jude Children’s Research Hospital, University of Houston, Tufts University School of Medicine and Fox Chase Cancer Center created a drug that can prevent flu-induced lung injury.

Strides Pharma Science Limited (Strides) today announced that its step‐ down wholly owned subsidiary, Strides Pharma Global Pte. Limited, Singapore, has received approval for Fluoxetine Tabs 10 mg and 20 mg, from the United States Food & Drug Administration (USFDA).

The product is bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD) Prozac® Tablets of Eli Lilly.

For heart attack patients, treating only the coronary artery that caused the infarction works just as well as preventive balloon dilation of the other coronary arteries, according to a new large study by researchers at Karolinska Institutet and others. The results are published in the New England Journal of Medicine.

Pfizer Inc announced positive top-line immunogenicity and safety data from the ongoing pivotal Phase 3 clinical trial (NCT05842967) MONeT (RSV IMmunizatiON Study for AdulTs at Higher Risk of Severe Illness),evaluating a single dose of ABRYSVO versus placebo in adults 18 to 59 years of age at risk of developing severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD).

Acertain variant of a key anti-inflammatory gene protects men under age 75 from severe illness and death when hospitalized from COVID-19, a genetic analysis of their blood shows.

Scientists at Uppsala University have discovered a new class of antibiotics with potent activity against multi-drug resistant bacteria, and have shown that it cures bloodstream infections in mice. The new antibiotic class is described in an article in the scientific journal PNAS.

The President of India Smt. Droupadi Murmu launched India’s first home-grown anti-Cancer CAR-T cell therapy and dedicated it to the Nation in the presence of the Governor of Maharashtra, Shri Ramesh Bais at the Indian Institute of Technology, (IIT) Bombay in Mumbai today. Also present on the occasion were Director, IIT Bombay, Prof. Subhasis Chaudhuri and Director, Tata Memorial Centre, Prof. Sudeep Gupta along with the key contributors including Prof. Rahul Purwar, Department of Bioscience and Bioengineering, IIT Bombay, and Dr. Hasmukh Jain and Dr.

Scientists at King’s have discovered a new cause for asthma that sparks hope for treatment that could prevent the life-threatening disease.